Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor Sir Rory Collins, Head of the Nuffield Department of Population Health, and Principal Investigator and Chief Executive of UK Biobank, has been awarded the Medical Research Council (MRC) Millennium Medal 2020, the MRC’s most prestigious personal award.

Professor Sir Rory Collins

Professor Sir Rory Collins is being honoured for his transformative national and international contributions to both cardiovascular disease and UK Biobank, including his discoveries showing that statins safely reduce the incidence of heart attacks and strokes in a wide range of individuals, which have saved millions of lives worldwide.

As the latest recipient of the MRC Millennium Medal, Professor Sir Rory Collins joins an elite group of men and women, including Sir Peter Mansfield, Professor Janet Darbyshire and Professor Sir Philip Cohen, for their exceptional contributions to medical research. Sir Rory will deliver a lecture and will be presented with the Medal commissioned from the Royal Mint at an awards ceremony in Spring 2021.

The full story is available on the Nuffield Department of Population Health website

It is also featured on th University of Oxford website

Similar stories

Wellcome accolades for Dr Douglas

Dr Alexander (Sandy) Douglas, an investigator at the Jenner Institute, Nuffield Department of Medicine, has recently received two prestigious Wellcome accolades.

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.

Com-COV vaccine mix-and-match study expands to 12-to-16-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a new study of COVID-19 vaccination schedules in young people aged 12 to 16.

Oxford announces the founding of the new Bennett Institute for Applied Data Science

The Bennett Institute for Applied Data Science at the University of Oxford has been established to pioneer the better use of data, evidence and digital tools in healthcare and policy, optimizing the impact of interventions to achieve improved outcomes.